ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Cantor Fitzgerald on ORIC Pharmaceuticals (ORIC): 'Solid Update in Prostate Cancer for ORIC-944'
May 29, 2025 6:20 AM EDTCantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on ORIC Pharmaceuticals (NASDAQ: ORIC)
The analyst comments "ORIC announced positive P1 data for ORIC-944 (oral PRC2 inhibitor) in prostate cancer. Confirmed PSA50 responses are tracking at ~50% in now a larger sample and starting to look differentiated compared to Pfizers... More
